OVERALL CHARACTERISTICS AND EARLY DIAGNOSIS OF PATIENTS WITH CONNECTIVE TISSUE DISEASES by László Czirják
10 Reumatizam 2015; Suppl 1: 10-13
Review paper Pregledni rad
Czirják L.
Overall characteristics and early diagnosis of patients 
with connective tissue diseases
10-13
OVERALL CHARACTERISTICS AND EARLY DIAGNOSIS OF PATIENTS WITH CONNECTIVE TISSUE 
DISEASES
SVEUKUPNA OBILJEŽJA I RANA DIJAGNOZA U BOLESNIKA S BOLESTIMA VEZIVNOG TKIVA 
László Czirják
Department of Rheumatology and Immunology, Medical Center, University of Pécs
Pécs, Hungary
Correspondence to:
Professor László Czirják, MD, PhD
Department of Rheumatology and Immunology, Medical Center, University of Pécs




sicca syndrome (dry eyes, dry mouth), pulmonary arterial 
hypertension/lung fibrosis, a variety of central and perip-
heral nervous system-related symptoms, and symmetric 
proximal muscle weakness and pain. Furthermore, prote-
inuria, hematuria, and recurrent pleuritis/pericarditis also 
belong to the disease spectrum of these disorders. Symp-
toms representing antiphospholipid syndrome (recurrent 
thrombo-embolic events, fetal morbidity, and presence of 
antiphospholipid autoantibodies) can also be typical con-
tributors. There are further rare findings, including per-
sistent peripheral/central nervous system-related symp-
toms, leukopenia, and pulmonary arterial hypertension. 
The early recognition of “unusual” associations of organ 
symptoms is a crucial point. 
Keywords: systemic autoimmune disease, systemic lupus 
erythematosus, systemic sclerosis, classification, treat-to-
target 
Abstract
The most important issue in regard to systemic autoimmu-
ne diseases is early recognition and early, long-term trea-
tment. In certain disorders, including rheumatoid arthritis 
and systemic sclerosis, the revised new classification crite-
ria help to identify the cases as early as possible. Once the 
diagnosis has been established, a “treat-to-target” approa-
ch is important. Further work is required to improve the 
currently available activity damage indexes and outcome 
measures in these particular disorders; in particular, better 
composite activity indexes seem to be necessary for the fu-
ture.
Early recognition of the typical symptoms and signs of 
these particular diseases is crucial. These disorders are 
usually accompanied by permanent or temporary inflam-
matory signs, and the inflammation often occurs in waves. 
The most frequent symptoms of systemic autoimmune 
disorders include polyarthritis, Raynaud phenomenon, 
inflammatory and non-inflammatory skin symptoms, 
plućnu hipertenziju / fibrozu pluća, različite simptome 
središnjega i perifernoga živčanog sustava te simetrič-
nu slabost i bol proksimalne muskulature. Osim toga, u 
spektar ovih specifičnih poremećaja pripadaju i protei-
nurija, hematurija te ponavljajući pleuritis/perikarditis. 
Simptomi tipični za antifosfolipidni sindrom (ponavlja-
jući trombo-embolijski događaji, fetalni morbiditet i pri-
sutnost antifosfolipidnih protutijela) mogu također biti 
obilježja ovih poremećaja. Rijetki nalazi uključuju stal-
ne simptome središnjega i perifernoga živčanog sustava, 
leukopeniju i plućnu hipertenziju. Stoga je ključno rano 
prepoznati „neobične” kombinacije organskih simptoma. 
Ključne riječi: sustavne autoimune bolesti, sistemski eritem-
ski lupus, sistemska skleroza, klasifikacija, liječenje prema 
cilju 
Sažetak
Najvažnije pitanje sustavnih autoimunih bolesti jest rano 
prepoznavanje i rano dugotrajno liječenje. U nekim bo-
lestima, uključujući reumatoidni artritis i sistemsku skle-
rozu, novi revidirani kriteriji mogu pomoći identificirati 
bolest što je prije moguće. Nakon postavljanja dijagnoze 
važno je „liječenje prema cilju”. Potrebni su dodatni napori 
za poboljšanje zasad dostupnih indeksa aktivnosti/ošteće-
nja i mjera ishoda u ovim bolestima, a napose bolji složeni 
indeksi aktivnosti koji se čine nužnima u budućnosti.
Ključno je rano prepoznati tipične simptome i znakove 
bolesti. Ove su bolesti obično praćene stalnim ili povre-
menim znakovima upale koja često nastupa u valovima. 
Najčešći simptomi sustavnih autoimunih bolesti uklju-
čuju poliartritis, Raynaudov fenomen, upalne i neupal-
ne simptome kože, „sicca” sindrom (suhe oči, suha usta), 
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Introduction
The early symptoms of systemic autoimmune diseases 
(Table 1) are usually highly variable, and the clinical pre-
sentations during their onset may often be very similar. 
One of the major hallmarks of these diseases is infla-
mmation. In general, inflammation can be caused by a 
great variety of infectious diseases, as well as by certain 
malignancies and autoimmune/auto- inflammatory dis-
orders. It is crucial that the systemic nature of the disease 
and the autoimmune phenomena should be recognized 
as early as possible. 
Clinical presentation of patients with connective tissue 
diseases 
One of the frequently present symptoms is symmetric 
polyarthritis affecting the metacarpophalangeal and 
proximal interphalangeal joint lines, as well as the lar-
ge joints (predominantly the knees and wrists). Other 
characteristic symptoms of connective tissue diseases 
(CTDs) include Raynaud phenomenon, inflammatory 
and non-inflammatory skin symptoms, sicca syndrome 
(dry eyes, dry mouth), pulmonary arterial hypertension/
lung fibrosis, a variety of central and peripheral nervo-
us system-related symptoms, and symmetric proximal 
muscle weakness and pain. Furthermore, proteinuria, he-
maturia, and recurrent pleuritis/pericarditis also belong 
to the wide disease spectrum of these particular disor-
ders. Symptoms representing antiphospholipid syndro-
me (recurrent thrombo-embolic events, fetal morbidity, 
and presence of antiphospholipid autoantibodies) can 
also be typical contributors to the disease spectrum. The-
re are further rare findings which may also be present, in-
cluding peripheral/central nervous system-related symp-
toms, leukopenia, and pulmonary arterial hypertension 
(Table 2). It is crucial to recognize “unusual” associations 
of different organ symptoms as early as possible; the lar-
ger the number of typical manifestations found, the more 
likely the diagnosis of a connective tissue disease is going 
to be.
In the presence of a combination of the most frequently 
observed phenomena, including Raynaud syndrome, 
polyarthritis, sicca syndrome, and skin symptoms, it is 
mandatory to think about the likelihood of a connective 
tissue disease. There  are several characteristic findings 
which may help in the evaluation of the patients (Table 
3).
Table 1 Systemic autoimmune diseases
Systemic autoimmune diseases
Table 2 The clinical spectrum of connective tissue diseases
The clinical spectrum of connective tissue diseases
Table 3 Characteristic findings during physical examination in connective 
tissue diseases
Lacrimal, salivary gland 
enlargement
Dry eyes, dry mouth
Lymphadenopathy
RA, other CTDs
Lack of peripheral arterial pulse
vasculitis

















Abbreviations used: SS - Sjögren syndrome, SSc - systemic sclerosis,  
DM-PM - dermato-polymyositis, RA - rheumatoid arthritis,  
SLE - systemic lupus erythematosus, aPS - antihpospholipid syndrome
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In the discussed disorders inflammation often occurs in 
waves, and there are periods when no signs of inflammati-
on can be observed. Apart from some rare cases, systemic 
inflammation is generally caused by a large variety of in-
fections, certain malignancies, and systemic autoimmune 
diseases. In many SLE cases an increased ESR without an 
acute phase reaction (i.e., increased CRP) may be present, 
while in infections and tumors both ESR and CRP are ele-
vated. It is therefore crucial to consider that connective 
tissue disease may be one of the important background 
causes of the inflammation. An extended search for the 
presence of an infectious/malignant disease without ta-
king immediate basic differential diagnostic steps for the 
presence of a CTD can cause a significant delay in the tre-
atment. In fact, there is a brief “window of opportunity” in 
the early phase of CTDs when the therapy usually effici-
ently stops the disease progression. 
Polyarthritis
A symmetric polyarthritis affecting the metacarpophalan-
geal and proximal interphalangeal lines as well as the large 
joints (predominantly knees and wrists) is often present 
in these disorders. Conversely, the distal interphalangeal 
(DIP) joints are not affected. In the differential diagnosis, 
infection-related arthritides, psoriatic arthritis, osteoar-
thritis, and chronic gout are especially important. 
Raynaud phenomenon
Raynaud phenomenon is an episodic digital vasospasm 
following an exposure to cold. Emotional stress may also 
be a provoking factor in some patients. Primary Raynaud 
phenomenon is a common disease, in which no other or-
gan manifestations, such as nailfold capillaroscopy chan-
ges or antinuclear antibodies, are present (1). Sometimes 
the patients may not notice the characteristic color chan-
ges (white-blue-red), and they complain about digital pain 
following exposure to cold. In case of secondary Raynaud 
syndrome, there is an underlying disease, as can often be 
observed in patients with connective tissue disease. Im-
portant basic differential diagnostic steps to be performed 
are nailfold capillary microscopy and antinuclear antibody 
screening test. As almost all SSc patients have Raynaud 
phenomenon, it is a very important indicator in early ca-
ses, especially if the patient in question also has puffy fin-
gers (2, 3, 4). 
Sicca syndrome is characterized by xerostomia and ke-
ratoconjunctivitis. Dryness of the mouth often causes 
difficulties in swallowing dry food, an inability to speak 
continuously, and a burning sensation. Ocular dryness ca-
uses a sandy or gritty feeling under the eyelids, burning, 
decreased tear production, redness, and itching. Dryne-
ss can result from many other causes, including diabetes 
mellitus and certain drugs with an anticholinergic effect 
(antidepressants, diuretics, anticholinergic agents, etc.). 
Infections such as hepatitis C and HIV and autonomic ne-
uropathy may also cause sicca symptoms. Dehydration or 
the use of diuretics are also possible background causes of 
xerostomia. 
One of the typical complaints is pain while climbing sta-
irs or combing one’s hair. Secondary causes can be due to 
drugs, infections, neurological disorders, and malignancy.
Exposure to UV light (from sunshine or the use of tanning 
boots) which provokes dermatitis is a frequent sign in SLE 
and dermatomyositis patients. Livedo reticularis is typical 
of primary/secondary antiphospholipid syndrome. In the 
latter case, the skin changes are stable. Palpable purpura 
(cutaneous vasculitis), gangrenes, sclerodactyly, and puffy 
fingers are also important signs of CTDs. Many other si-
gns, including telangiectasia, skin pigmentary changes, or 
deep necrotic vasculitic lesions, may also be present. 
Proteinuria, hematuria
The kidney involvement does not cause complaints, there-
fore an early detection is exclusively based on the urinal-
ysis. Signs of proteinuria, hematuria, and cylindruria can 
be important findings, especially in patients with SLE or 
ANCA-associated vasculitic syndromes. 
The clinical manifestations of APS include recurrent ar-
tiral-venous thromboses and thromboembolic events, 
recurrent miscarriages, and obstetric events. Many other 
manifestations, including decreased platelet count, val-
vulopathy, livedo reticularis, or pulmonary hypertension, 
can also be present. 
Basic investigations for diagnosis verification
Besides the antinuclear antibody (ANA) screening test, 
other investigations, including rheumatoid factor, ANCA, 
and antiphospholipid antibody tests (anticardiolipin IgG 
and IgM, lupus anticoagulant, and anti-beta2 glycoprotein 
I), may also be necessary. The other basic screening test 
is nailfold capillaroscopy, which is a crucial investigation 
in cases presenting with Raynaud phenomenon (2, 3). 
Giant capillaries, capillary dropout, and hemorrhages are 
important signs, predominantly present in cases with SSc, 
MCTD, and, less frequently, in inflammatory myopathies 
and UCTD. The presence of Raynaud syndrome and sc-
leroderma capillary pattern may be an important indica-
tor of a potential CTD, mainly in the scleroderma disease 
spectrum. 
Early diagnosis is crucial because of the window of op-
portunity in the early phase of the disease when the tre-
atment seems to be most efficient. This fact prompted the 
experts in the field to revise several classification criteria, 
including SSc to involve patients with very early disease 
manifestations (5, 6, 7). Furthermore, a definition of the 
very early phase of the disease helps to identify the cases as 
early as possible (6, 7).
Classification criteria and “treat-to-target” approach 
Once the diagnosis of a CTD has been established, the 
“treat-to-target” approach is the important next step in 
the management of a particular patient. The treatment 
strategy for several chronic diseases has been profoundly 
changed in the last two decades, and the predominantly 
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symptom-based management has been successfully 
changed to a target-based approach. This first happened 
with the management of hypertension and diabetes. In 
rheumatology, the management of rheumatoid arthritis 
(RA) has also changed remarkably, based on the results 
of several randomized clinical trials showing that the tar-
geted therapy approach using composite disease activity 
scores yielded more favorable outcomes with regard to 
the extent of joint damage and function (8, 9). Recently, 
a “treat-to-target” recommendation has been developed 
and widely used in the treatment of patients with RA as 
well as gout (10, 11). In systemic autoimmune diseases 
the measurement of outcome based on composite disease 
activity scores seems to be difficult. Further work is requ-
ired to improve the currently available activity damage 
indexes in these particular disorders; in particular, better 
composite activity indexes seem to be necessary for the 
future. Furthermore, systemic autoimmune diseases, es-
pecially SLE, show a slowly progressive accumulation of 
irreversible organ damage, and the presence of damage is 
a predictor of further damage accrual (12). Based on these 
facts, it is reasonable to formulate a treat-to-target reco-
mmendation like the one established for SLE, as well as to 
define some new treatment targets beside prevention of 
damage accrual or flare up, which have been recognized 
as important treatment goals (13, 14). 
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